Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
Margherita Rimini(Vita-Salute San Raffaele University), Su Yung‐Yeh(National Health Research Institutes), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Michele Ghidini(University of Insubria), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Elisabetta Fenocchio(Candiolo Cancer Institute), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Emiliano Tamburini(Ospedale Infermi di Rimini), Masafumi Ikeda(National Cancer Center Hospital East), Anna Saborowski(Medizinische Hochschule Hannover), Alessandro Pastorino(Ospedale Policlinico San Martino), Lucrezia Zumstein(Hospital Universitario 12 De Octubre), Alessandro Parisi(Marche Polytechnic University), Gerald W. Prager(Comprehensive Cancer Center Vienna), Lukas Perkhofer(University Hospital Ulm), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Giovanni Farinea(University of Turin), Caterina Vivaldi(Scuola Superiore Sant'Anna), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), C. Pinto(Harvard University), Gian Paolo Spinelli(Sapienza University of Rome), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Mario Scartozzi(University of Cagliari), Matteo Landriscina(University of Foggia), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Hong Jae Chon(CHA University Bundang Medical Center), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Ingrid Garajová(University of Parma), Chiara Pircher(Fondazione IRCCS Istituto Nazionale dei Tumori), Federico Nichetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Beodeul KANG, Frederik Peeters, Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nuno Couto(Champalimaud Foundation), Changhoon Yoo(Ulsan College), A. Martirena(Hospital Universitario Fundación Jiménez Díaz), Jin Won Kim(Korea University Medical Center), Il Hwan Kim(Inje University Haeundae Paik Hospital), Fabian Fimkelmeier(Goethe University Frankfurt), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Emanuela Dell’Aquila(Università Campus Bio-Medico)
Cited by 10
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k